Feb 16, 2023 / 03:00PM GMT
David Reed Risinger - SVB Securities LLC, Research Division - Senior MD
Great. Good morning, everybody, and thank you for participating in the final day of our SVB Global Healthcare Conference. My name is Dave Risinger. I cover diversified biopharmaceuticals, and it's very much my pleasure to welcome leaders from the Pfizer leadership team.
So with us this morning, we have Andy Schmeltz. He's Senior Vice President of Commercial Strategy and Innovation; and Navin Katyal, who is U.S. Commercial and Global Business Lead for the mRNA portfolio. So we're fortunate to have them both here with us today, and just wanted to extend my thanks to you both for taking the time to join us.
Questions and Answers:
David Reed Risinger - SVB Securities LLC, Research Division - Senior MDI thought we'd start off with a high-level question for you, Andy. I know that you obviously kicked off a very helpful discussion on Pfizer's innovation initiatives at your analyst meeting in early December. But it would be helpful for you to just sort of summarize that, highlight
Trustpilot
